- Previous Close
0.7728 - Open
0.7501 - Bid 0.7601 x 1300
- Ask 0.9889 x 1100
- Day's Range
0.6736 - 0.7500 - 52 Week Range
0.6200 - 8.5500 - Volume
64,699 - Avg. Volume
94,006 - Market Cap (intraday)
12.955M - Beta (5Y Monthly) 1.32
- PE Ratio (TTM)
-- - EPS (TTM)
-3.9000 - Earnings Date Nov 14, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
16.00
BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. The company's product pipeline also includes BX004, a phage therapy for cystic fibrosis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.
www.biomx.comRecent News: PHGE
View More
Performance Overview: PHGE
Trailing total returns as of 11/13/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PHGE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PHGE
View MoreValuation Measures
Market Cap
12.95M
Enterprise Value
23.66M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
6.54
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-32.65%
Return on Equity (ttm)
-121.29%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-26.25M
Diluted EPS (ttm)
-3.9000
Balance Sheet and Cash Flow
Total Cash (mrq)
31.61M
Total Debt/Equity (mrq)
36.08%
Levered Free Cash Flow (ttm)
-17.37M
Research Analysis: PHGE
View MoreCompany Insights: PHGE
PHGE does not have Company Insights